Target-tissue-specific antigen-binding molecule
Antigen-binding molecules with concentration-dependent activity address the challenge of target tissue specificity, enabling effective therapy on cancer or inflamed tissues while reducing side effects on normal tissues.
Patent Information
- Authority / Receiving Office
- AU · AU
- Patent Type
- Applications
- Current Assignee / Owner
- CHUGAI PHARMA CO LTD
- Filing Date
- 2023-09-12
- Publication Date
- 2026-07-23
AI Technical Summary
Existing antibody pharmaceuticals face challenges in achieving target tissue-specific cytotoxic activity while minimizing side effects on normal tissues due to antigen expression in both cancer and normal cells, and there is a lack of techniques for reversible action at lesion sites without systemic effects.
Development of antigen-binding molecules with varying antigen-binding activity based on the concentration of target tissue-specific compounds, such as kynurenine or its precursors, allowing for selective binding and action at lesion sites like cancer or inflamed tissues.
The antigen-binding molecules provide targeted therapeutic effects on cancer or inflamed tissues while minimizing side effects on normal tissues by varying binding activity based on tissue-specific metabolite concentrations.
Smart Images

Figure 00000309_0000 
Figure 00000310_0000 
Figure 00000311_0000
Abstract
Citation Information
Patent Citations
AUG19,2010
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2009125825A1
Novel modulators
WO2011038302A2